Switzerland as a pharmaceutical hub: the key points at a glance

Switzerland as a pharmaceutical hub: the key points at a glance
Testing laboratory at the EMPA

As a highly specialized production location for pharmaceutical products, Switzerland enjoys an excellent reputation the world over. Both multinational corporations and small and medium-sized pharmaceutical companies benefit from ideal infrastructure and well-trained professionals here. The coexistence of small and large companies and the proximity to research institutions also contribute to creating an ideal climate for research and innovation. 

The presence of highly qualified scientists and pharmaceutical talent from the world’s leading universities make a significant contribution towards developing new medicines. Novartis reported a total of 660 patent applications in 2012, while Roche reported 460 in the same year.

The framework conditions are also in place: the Swiss healthcare system supports the introduction of new medicines and, in doing so, offers companies access to a sophisticated test and sales market.

In addition to Switzerland, international markets play a decisive role. The pharmaceutical industry produced more than a third of all Swiss exports in 2014. This is a significant increase compared to the year 2000, where pharmaceutical exports represented just 18% of total exports. Value added in the pharmaceutical industry has continued to increase over the last decade in Switzerland. The growth rate amounted to an average of 9.1% each year between 2002 and 2012. This is the highest growth rate compared to other countries; the Netherlands and Germany have achieved a significantly lower increase in value added of around 6%. 

Switzerland is by far the most important stock exchange for Life Sciences companies in Europe. Around a third of market capitalization on the SIX Swiss Exchange is attributable to Life Sciences companies. 42% of the capitalization of European Life Sciences companies is listed on the SIX.

Download the pharmaceutical technology fact sheet

Global,

As a highly specialized production location for pharmaceutical products, Switzerland enjoys an excellent reputation the world over. Both multinational corporations and small and medium-sized pharmaceutical companies benefit from ideal infrastructure and well-trained professionals here. The coexistence of small and large companies and the proximity to research institutions also contribute to creating an ideal climate for research and innovation. 

The presence of highly qualified scientists and pharmaceutical talent from the world’s leading universities make a significant contribution towards developing new medicines. Novartis reported a total of 660 patent applications in 2012, while Roche reported 460 in the same year.

The framework conditions are also in place: the Swiss healthcare system supports the introduction of new medicines and, in doing so, offers companies access to a sophisticated test and sales market.

In addition to Switzerland, international markets play a decisive role. The pharmaceutical industry produced more than a third of all Swiss exports in 2014. This is a significant increase compared to the year 2000, where pharmaceutical exports represented just 18% of total exports. Value added in the pharmaceutical industry has continued to increase over the last decade in Switzerland. The growth rate amounted to an average of 9.1% each year between 2002 and 2012. This is the highest growth rate compared to other countries; the Netherlands and Germany have achieved a significantly lower increase in value added of around 6%. 

Switzerland is by far the most important stock exchange for Life Sciences companies in Europe. Around a third of market capitalization on the SIX Swiss Exchange is attributable to Life Sciences companies. 42% of the capitalization of European Life Sciences companies is listed on the SIX.

Download the pharmaceutical technology fact sheet

Page Meta 
Fact Sheet
  • Swiss Business Hub India
    Senior Investment Advisor
    502 Dalamal House, 5th Floor, 206, Jamnalal Bajaj Marg, Nariman Point, Mumbai
    +91 22 4343 56 00
  • Swiss Business Hub India
    Head of Swiss Business Hub India
    502 Dalamal House, 5th Floor, 206, Jamnalal Bajaj Marg, Nariman Point, Mumbai
    +91 22 4343 56 00

Explore Leading Companies – Pharmaceuticals